KM Research Hub
DIGITIZATION RESULTS

KM 曲线提取结果

共 239 篇,按论文发表时间从新到旧排列。

论文发表日期KM Figure面板成功提取曲线数状态
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.PMID 40996773 · JAMA Oncol 2025-Nov-01 25510 提取完成
Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.PMID 40641008 · J Clin Pharmacol 2025-Nov 1224 质量警告
Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer.PMID 40680993 · Ann Oncol 2025-Nov 1112 提取完成
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial.PMID 40899645 · Cancer Commun (Lond) 2025-Nov 4242238 部分完成
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.PMID 40913104 · Leukemia 2025-Nov 1335 质量警告
Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.PMID 40976711 · Cancer Sci 2025-Nov 2336 提取完成
Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment.PMID 41167084 · ESMO Open 2025-Nov 38823 质量警告
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.PMID 41184595 · Target Oncol 2025-Nov 1339 提取完成
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.PMID 41320342 · ESMO Open 2025-Nov 3559 质量警告
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor.PMID 41173494 · J Immunother Cancer 2025-Oct-31 1335 质量警告
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.PMID 40737596 · Blood 2025-Oct-30 28824 提取完成
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.PMID 41052510 · Lancet 2025-Oct-25 26611 质量警告
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.PMID 40902136 · J Clin Oncol 2025-Oct-10 2448 提取完成
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).PMID 41052983 · Blood Cancer J 2025-Oct-06 3336 提取完成
Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer: A Randomized Clinical Trial.PMID 41032300 · JAMA Netw Open 2025-Oct-01 1336 提取完成
Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma.PMID 40613748 · CPT Pharmacometrics Syst Pharmacol 2025-Oct 1215 部分完成
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.PMID 40750932 · Nat Med 2025-Oct 6272754 提取完成
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib.PMID 41139117 · ESMO Open 2025-Oct 2324 部分完成
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.PMID 40523203 · J Clin Oncol 2025-Sep-20 1100 提取失败
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.PMID 40198878 · Blood 2025-Sep-11 2226 提取完成
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.PMID 40454705 · J Clin Oncol 2025-Sep-10 1113 提取完成
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.PMID 40569606 · Clin Cancer Res 2025-Sep-02 1224 提取完成
Covered versus uncovered endoluminal stenting in the acute management of obstructing colorectal cancer in the palliative setting: randomized clinical trial (CReST2).PMID 40966674 · Br J Surg 2025-Sep-02 1223 质量警告
Chemoradiotherapy With or Without Simultaneous Integrated Boost for Cervical Cancer With Full-Thickness Stromal Invasion: A Phase 3 Randomized Clinical Trial.PMID 40971156 · JAMA Netw Open 2025-Sep-02 1336 提取完成
Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331.PMID 40515508 · Pediatr Blood Cancer 2025-Sep 22210 提取完成
Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study.PMID 40958065 · Target Oncol 2025-Sep 14416 提取完成
Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study.PMID 40866342 · Signal Transduct Target Ther 2025-Aug-28 2224 质量警告
The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy.PMID 40851062 · BMC Cancer 2025-Aug-25 3111119 质量警告
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.PMID 40623279 · J Clin Oncol 2025-Aug-20 1668 质量警告
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.PMID 40127397 · Blood 2025-Aug-07 1225 质量警告